KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medpace Holdings (MEDP) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Medpace Holdings (MEDP) over the last 11 years, with Q3 2025 value amounting to $235.5 million.

  • Medpace Holdings' Free Cash Flow rose 6998.66% to $235.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $676.8 million, marking a year-over-year increase of 2634.56%. This contributed to the annual value of $572.3 million for FY2024, which is 4424.74% up from last year.
  • Latest data reveals that Medpace Holdings reported Free Cash Flow of $235.5 million as of Q3 2025, which was up 6998.66% from $142.4 million recorded in Q2 2025.
  • In the past 5 years, Medpace Holdings' Free Cash Flow ranged from a high of $235.5 million in Q3 2025 and a low of $37.0 million during Q1 2022
  • For the 5-year period, Medpace Holdings' Free Cash Flow averaged around $107.8 million, with its median value being $103.5 million (2024).
  • Per our database at Business Quant, Medpace Holdings' Free Cash Flow plummeted by 3677.54% in 2021 and then soared by 10857.96% in 2024.
  • Over the past 5 years, Medpace Holdings' Free Cash Flow (Quarter) stood at $61.8 million in 2021, then surged by 106.29% to $127.4 million in 2022, then increased by 14.88% to $146.4 million in 2023, then increased by 25.01% to $183.0 million in 2024, then rose by 28.67% to $235.5 million in 2025.
  • Its Free Cash Flow was $235.5 million in Q3 2025, compared to $142.4 million in Q2 2025 and $115.8 million in Q1 2025.